Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus

This publication has 14 references indexed in Scilit:

• LDL Containing Apolipoprotein CIII Is an Independent Risk Factor for Coronary Events in Diabetic Patients
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2003
• Effect of pravastatin on apolipoproteins B and C-III in very-low-density lipoproteins and low-density lipoproteins
  The American Journal of Cardiology, 2002
• Insulin resistance syndrome and type 2 diabetes mellitus
  The American Journal of Cardiology, 2001
• VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial
  Circulation, 2000
• Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in Type II diabetes
  Diabetologia, 2000
• Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.
  Journal of Clinical Investigation, 1997
• The Role of Triglyceride-Rich Lipoprotein Families in the Progression of Atherosclerotic Lesions as Determined by Sequential Coronary Angiography From a Controlled Clinical Trial
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1997
• Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E
  Atherosclerosis, 1990
• Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
  Journal of Clinical Investigation, 1986
• Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.
  Journal of Clinical Investigation, 1985